Kenya’s Ministry of Health has taken a major step in HIV prevention by recommending the registration of Lenacapavir, a groundbreaking long-acting antiretroviral medicine. The Pharmacy and Poisons Board has approved both the 300 mg tablet and 464 mg injectable solution forms of Lenacapavir for use as pre-exposure prophylaxis (PrEP). This follows global recognition of the […]
